Aliskiren

證據等級: L5

預測適應症: 10 個

Aliskiren: From Hypertension to Pulmonary Hypertension owing to Lung Disease and/or Hypoxia

One-Sentence Summary

Aliskiren is the first orally active direct renin inhibitor, used clinically for the treatment of arterial hypertension by blocking the rate-limiting step of the renin-angiotensin-aldosterone system (RAAS). The TxGNN model predicts it may be effective for pulmonary hypertension owing to lung disease and/or hypoxia, with no clinical trials and 20 publications retrieved — however, none of the publications directly investigate Aliskiren in this indication, leaving the prediction without specific clinical or preclinical support.

Quick Overview

Item	Content
Original Indication	Hypertension (direct renin inhibitor; not registered in Taiwan)
Predicted New Indication	Pulmonary Hypertension owing to Lung Disease and/or Hypoxia
TxGNN Prediction Score	99.98%
Evidence Level	L5
Taiwan Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data was not available in this Evidence Pack. Based on pharmacological class, Aliskiren is a direct renin inhibitor — the first in its class to receive clinical approval. It acts at the most upstream point of the RAAS by binding directly to renin and blocking its catalytic activity, thereby suppressing the generation of angiotensin I, and consequently angiotensin II (Ang II) and aldosterone. Ang II is known to induce pulmonary vasoconstriction via AT1 receptors, which provides the theoretical basis for the TxGNN model’s prediction.

Pulmonary hypertension owing to lung disease and/or hypoxia (WHO Group 3 PH) develops primarily through hypoxic pulmonary vasoconstriction (HPV) and hypoxia-driven vascular remodeling mediated by the HIF-1α/endothelin-1 axis. Unlike renovascular or essential hypertension — where RAAS is the dominant driver — Group 3 PH is governed by oxygen-sensing pathways. RAAS plays only a secondary, modulatory role in this disease context. While Ang II contributes to pulmonary vascular tone, renin inhibition alone is unlikely to adequately address the underlying HIF-1α-driven remodeling and right ventricular pressure overload that characterize this condition.

The 20 retrieved publications address general hypoxia biology — neurological effects, tumor microenvironment, immunity — without any paper examining Aliskiren in pulmonary hypertension or lung disease models. The mechanistic link therefore remains theoretical and extremely weak, insufficient to support advancement beyond AI model prediction at this time.

Clinical Trial Evidence

Currently no related clinical trials registered for Aliskiren in pulmonary hypertension owing to lung disease and/or hypoxia.

Literature Evidence

All 20 retrieved publications address general hypoxia biology and are not specific to Aliskiren or pulmonary hypertension from lung disease. The 10 most contextually relevant entries are listed below for background reference.

PMID	Year	Type	Journal	Key Findings
11172576	2000	Review	Respiratory Care Clinics	Reviews four mechanisms of hypoxemia (hypoventilation, V/Q mismatch, right-to-left shunt, diffusion impairment) directly relevant to Group 3 PH pathophysiology; does not address Aliskiren
21328446	2011	Review	Journal of Cellular Biochemistry	Oxygen sensing governs angiogenesis, vascular disease, and pH homeostasis; overview of HIF pathway and hypoxia-related disease mechanisms; does not address Aliskiren
28972206	2017	Review	Nature Reviews Immunology	Hypoxia regulates innate and adaptive immunity in physiological and pathological niches; relevant to vascular remodeling context; does not address Aliskiren
27423661	2016	Review	Cell and Tissue Research	HIF-1-mediated adaptation drives tissue repair; chronic hypoxia shifts balance toward pathological fibrosis and vascular remodeling; does not address Aliskiren
34535359	2021	Review	Clinical Oncology	Tumor hypoxia induces resistance to radiation and immunotherapy; discusses strategies to therapeutically modify hypoxia; does not address Aliskiren
39841808	2025	Review	Science Translational Medicine	Chronic continuous hypoxia shows preclinical benefits in mitochondrial disease and ischemia models; translation to patients faces major safety barriers; does not address Aliskiren
33862277	2021	Review	Ageing Research Reviews	Hypoxia is pivotal in Alzheimer’s and other neurodegenerative diseases; reduced ambient oxygen may exert protective effects in aging; does not address Aliskiren
40963621	2025	Review	Frontiers in Immunology	HIF-1α mediates shared molecular mechanisms across tumor progression and autoimmune disease; does not address Aliskiren
34618295	2022	Review	Metabolic Brain Disease	Acute and chronic hypoxia cause neurological deficits including cognitive dysfunction; reviews clinical and molecular evidence; does not address Aliskiren
37915135	2023	Review	BMB Reports	CMGC kinases regulate HIF abundance in tumor hypoxia, with implications for angiogenesis and therapy resistance; does not address Aliskiren

Safety Considerations

Please refer to the SmPC for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a very high TxGNN prediction score (99.98%), the mechanistic link between renin inhibition and Group 3 pulmonary hypertension is weak — the core pathophysiology (hypoxic pulmonary vasoconstriction and HIF-1α/ET-1-driven vascular remodeling) is not primarily RAAS-dependent, no clinical trials or Aliskiren-specific literature support this indication, and known safety signals from the ALTITUDE trial (increased renal and cardiovascular events with RAAS blockade in high-risk patients) counsel caution before pursuing new indications.

To proceed, the following is needed:

Preclinical studies in hypoxia-exposed animal models of pulmonary hypertension to test whether renin inhibition reduces right ventricular pressure or pulmonary vascular remodeling
Mechanistic research quantifying the contribution of RAAS/renin to Group 3 PH relative to HIF-1α and ET-1 pathways
TFDA SmPC review (warnings, contraindications, drug interactions) to complete the safety profile
MOA data from DrugBank API to confirm pharmacological target, receptor selectivity, and off-target activity relevant to pulmonary vasculature
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.